Format

Send to

Choose Destination
Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364-6. doi: 10.1016/j.vaccine.2017.09.092. [Epub ahead of print]

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.

Author information

1
World Health Organisation, Geneva, Switzerland. Electronic address: vekemansj@who.int.
2
World Health Organisation, Geneva, Switzerland.
3
INCLEN Institute of Global Health, New Delhi, India.
4
Walter Reed Army Institute of Research, Silver Spring, USA.
5
London School of Hygiene & Tropical Medicine, London, UK.
6
John Hopkins Bloomberg School of Public Health, Baltimore, USA.
7
National Institute of Health, Bethesda, USA.
8
PATH, Seattle, USA.

Abstract

The respiratory syncytial virus causes a considerable respiratory disease burden globally, most markedly in young infants, in low and middle income countries. A diverse product pipeline illustrates the recent intensification of research and development activities for vaccines and monoclonal antibodies against RSV. With the aim to ensure that product development activities are directed to address the public health needs, the World Health Organization has developed a research and development technical roadmap and articulated product characteristics preferences.

KEYWORDS:

Maternal immunization; Research and development; Respiratory syncytial virus; Vaccines

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center